Mar­ket­ingRx roundup: Pfiz­er talks about its ‘Char­lie’ AI mar­ket­ing bot; Gilead pledges $12M for HIV pre­ven­tion

Pfiz­er opens up about its gen­er­a­tive AI mar­ket­ing plat­form: The drug­mak­er is rolling out a new ar­ti­fi­cial in­tel­li­gence plat­form for mar­ket­ing — named “Char­lie” af­ter its founder Charles Pfiz­er — and is one of chief mar­ket­ing of­fi­cer Drew Panayiotou’s “big bets” for 2024. Panayiotou de­scribed Char­lie as Pfiz­er’s “AI-pow­ered mar­ket­ing work­bench” in a LinkedIn post last week, not­ing it’s “de­signed to ac­cel­er­ate col­lab­o­ra­tion, ideation and cam­paign de­vel­op­ment” be­tween the com­pa­ny and its agen­cies around the world. More de­tails about the plat­form and Pfiz­er’s plans for its fu­ture were re­port­ed by Digi­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER